Nephrol Dial Transplant (2001) 16: 987-993
© 2001 European Renal Association-European Dialysis and Transplant Association
Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets
1 Department of Internal Medicine, 2 Research Institute for Internal Medicine, National Hospital, Oslo, Norway
Background. A single bolus of dalteparin at the start of haemodialysis (HD) may prevent clot formation, but subclinical activation of platelets and coagulation may still occur. Consequently, the relationship between clinical clotting events and activation markers of platelets and coagulation before and during HD is of interest.
Methods. The effect of tapered doses of dalteparin during 84 HD sessions (4–4.5 h) was prospectively examined in 12 patients. Six of the patients were treated with warfarin. The initial dalteparin dose was reduced to 50% if no clotting was observed. Clinical clotting was evaluated by inspection of the air trap every hour and by inspection of the dialyser after each session. Anti-FXa activity was measured for assessment of dalteparin activity. Markers of activated plasma coagulation, (thrombin-antithrombin (TAT) and prothrombin fragment 1+2 (PF1+2)) and a marker of platelet activation (ß-thromboglobulin, ß-TG), were measured before the start of and after 3 and 4 h of dialysis. Ten pre-dialytic patients with chronic renal failure served as a control group. A total sof 230 measurements of each parameter were performed.
Results. An anti-FXa activity above 0.4 IU/ml at the end of HD inhibits overt clot formation for 4 h. This was obtained by an intravenous dalteparin dose of about 5000 IU. TAT and PF1+2 correlated to clinical clotting episodes (r=0.50 and 0.47, P<0.001). ß-TG was not significantly correlated to clinical clotting. All parameters increased during the sessions (TAT, PF1+2, ß-TG, P<0.001). When measurements during clinical clotting episodes were disregarded, all parameters were still markedly increased. Warfarin-treated patients had lower TAT and PF1+2. Dialysis patients had higher ß-TG values than pre-dialytic patients.
Conclusion. Despite clinically effective anticoagulation, obtained by dalteparin administration, platelets and coagulation are activated by HD, resulting in a potentially thrombophilic state. Warfarin treatment reduces clinical clot formation and subclinical activation of coagulation.
Keywords: dalteparin; haemodialysis; plasmin antiplasmin; prothrombin fragment 1+2 (PF1+2); thrombin-antithrombin; ß-thromboglobulin
Correspondence and offprint requests to: Dr Solbjørg Sagedal, Med.avd., Rikshospitalet, N-0027 Oslo, Norway.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Naumnik, K. Pawlak, and M. Mys'liwiec Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study Clinical and Applied Thrombosis/Hemostasis, February 1, 2009; 15(1): 84 - 91. [Abstract] [PDF]
|
|
|
|
|
|
S. E. ElChoufani, P. Bolin, S. Waien, C. R. Christiano, D. Holbert, and A. P. Bode Platelet Adhesion Testing May Predict Early Hemodialysis Arteriovenous Graft and Fistula Failure in End-Stage Renal Disease Patients Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 399 - 409. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Chanard, S. Lavaud, H. Maheut, I. Kazes, F. Vitry, and P. Rieu The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Stasko, P. Galajda, J. Ivankova, P. Holly, E. Rozborilova, and P. Kubisz Soluble P-Selectin During a Single Hemodialysis Session in Patients With Chronic Renal Failure and Erythropoietin Treatment Clinical and Applied Thrombosis/Hemostasis, October 1, 2007; 13(4): 410 - 415. [Abstract] [PDF]
|
|
|
|
|
|
B. Naumnik, J. Borawski, K. Pawlak, and M. Mysliwiec Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-{beta}1 during haemodialysis: a cross-over study Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1690 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sagedal, A. Hartmann, K. Osnes, S. Bjornsen, J. Torremocha, P. Fauchald, J. Kofstad, and F. Brosstad Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin Nephrol. Dial. Transplant., February 1, 2006; 21(2): 444 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pertosa, S. Simone, M. Soccio, D. Marrone, L. Gesualdo, F. P. Schena, and G. Grandaliano Coagulation Cascade Activation Causes CC Chemokine Receptor-2 Gene Expression and Mononuclear Cell Activation in Hemodialysis Patients J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2477 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sagedal Prevention of activation of coagulation during haemodialysis and the use of warfarin Nephrol. Dial. Transplant., March 1, 2004; 19(3): 749 - 749. [Full Text] [PDF]
|
|
|
|
|
|
B. Naumnik, J. Borawski, and M. Mysliwiec Reply Nephrol. Dial. Transplant., March 1, 2004; 19(3): 749 - 750. [Full Text] [PDF]
|
|
|
|
|
|
M. Trovati and F. Cavalot Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. Droste, T. Beyna, B. Frye, V. Schulte, E. B. Ringelstein, and R. M. Schaefer Reduction of circulating microemboli in the subclavian vein of patients undergoing haemodialysis using pre-filled instead of dry dialysers Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2377 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lavaud, E. Canivet, A. Wuillai, H. Maheut, C. Randoux, J.-M. Bonnet, J.-L. Renaux, and J. Chanard Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2097 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Naumnik, J. Borawski, and M. Mysliwiec Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study Nephrol. Dial. Transplant., July 1, 2003; 18(7): 1376 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chanard, S. Lavaud, C. Randoux, and P. Rieu New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding Nephrol. Dial. Transplant., February 1, 2003; 18(2): 252 - 257. [Full Text] [PDF]
|
|